Cabaletta Bio, Inc. (CABA)
0.9361
-0.07
(-7.32%)
USD |
NASDAQ |
Nov 20, 16:00
0.9397
0.00 (0.00%)
After-Hours: 20:00
Cabaletta Bio Enterprise Value : -74.27M for Nov. 20, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 20, 2026 | -74.27M |
| November 19, 2026 | -58.33M |
| November 18, 2026 | -48.62M |
| November 17, 2026 | -56.17M |
| November 16, 2026 | -36.76M |
| November 13, 2026 | -0.0869M |
| November 12, 2026 | 10.70M |
| November 11, 2026 | 36.59M |
| November 10, 2026 | 36.59M |
| November 09, 2026 | 47.37M |
| November 06, 2026 | 4.228M |
| November 05, 2026 | -0.0869M |
| November 04, 2026 | 30.11M |
| November 03, 2026 | 30.11M |
| November 02, 2026 | 32.27M |
| October 30, 2026 | 49.53M |
| October 29, 2026 | 65.71M |
| October 28, 2026 | 51.69M |
| October 27, 2026 | 37.66M |
| October 26, 2026 | 15.01M |
| October 23, 2026 | 40.90M |
| October 22, 2026 | 51.69M |
| October 21, 2026 | 56.00M |
| October 20, 2026 | 71.10M |
| October 19, 2026 | 43.06M |
| Date | Value |
|---|---|
| October 16, 2026 | 27.96M |
| October 15, 2026 | 58.16M |
| October 14, 2026 | 73.26M |
| October 13, 2026 | 88.36M |
| October 12, 2026 | 109.93M |
| October 09, 2026 | 140.13M |
| October 08, 2026 | 144.45M |
| October 07, 2026 | 148.76M |
| October 06, 2026 | 159.55M |
| October 05, 2026 | 172.49M |
| October 02, 2026 | 155.23M |
| October 01, 2026 | 131.50M |
| September 30, 2026 | 137.97M |
| September 29, 2026 | 132.71M |
| September 28, 2026 | 136.06M |
| September 25, 2026 | 147.81M |
| September 24, 2026 | 162.06M |
| September 23, 2026 | 172.96M |
| September 22, 2026 | 219.93M |
| September 21, 2026 | 213.22M |
| September 18, 2026 | 228.31M |
| September 17, 2026 | 233.35M |
| September 16, 2026 | 218.25M |
| September 15, 2026 | 235.86M |
| September 14, 2026 | 288.70M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Agenus, Inc. | 453.57M |
| Amgen, Inc. | 276.45B |
| Anika Therapeutics, Inc. | 158.39M |
| BioCryst Pharmaceuticals, Inc. | 2.302B |
| Imunon, Inc. | 6.224M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -53.05M |
| Total Expenses (Quarterly) | 53.05M |
| EPS Diluted (Quarterly) | -0.284 |
| Earnings Yield | -152.5% |
| Normalized Earnings Yield | -152.46 |